{
  "20150152125": {
    "inventor": "MORGAN; Lee R.",
    "report_date": "June 4, 2015",
    "title": "SALTS OF ISOPHOSPHORAMIDE MUSTARD AND ANALOGS THEREOF AS ANTI-TUMOR AGENTS",
    "abstract": "The present disclosure relates to salts and compositions of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formula I: (I) wherein A.sup.+ represents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and formulating pharmaceutical compositions thereof. Methods for administering the disclosed compounds to subjects, particularly to treat hyper-proliferative disorders, also are disclosed. ##STR00001##",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20140378704": {
    "inventor": "WALIGORA; Frank W.; et al.",
    "report_date": "December 25, 2014",
    "title": "SYNTHESIS AND FORMULATIONS OF SALTS OF ISOPHOSPHORAMIDE MUSTARD AND ANALOGS THEREOF",
    "abstract": "Disclosed herein are formulations and methods of manufacture of compounds of formula (E): ##STR00001## wherein X and Y independently represent leaving groups; and A.sup.+ is an ammonium cation.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=2&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20140212495": {
    "inventor": "Papadopoulos; Pavlos; et al.",
    "report_date": "July 31, 2014",
    "title": "NANOPARTICULATE COMPOSITIONS OF TUBULIN INHIBITOR COMPOUNDS",
    "abstract": "The present invention is directed to novel pharmaceutical compositions comprising nano- and micro-particulate formulations of poorly water soluble tubulin inhibitors of the indole chemical class, preferably N-substituted indol-3-glyoxyamides, and more preferably N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]glyoxylic acid amide (D-24851), also known as \"Indibulin,\" and methods of making and using such compositions for the treatment of anti-tumor agent resistant cancers and other diseases.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=3&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20140194377": {
    "inventor": "AMEDIO, JR.; John C.; et al.",
    "report_date": "July 10, 2014",
    "title": "Salts of Isophosphoramide Mustard and Analogs Thereof",
    "abstract": "Disclosed herein are crystalline compounds of formula (I) ##STR00001## wherein A.sup.+ represents a hydroxylated aliphatic ammonium species; and X and Y independently represent leaving groups.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=4&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20140193519": {
    "inventor": "Wallner; Barbara P.; et al.",
    "report_date": "July 10, 2014",
    "title": "INDIBULIN THERAPY",
    "abstract": "The invention provides combination therapy, wherein one or more other therapeutic agents are administered with indibulin or a pharmaceutically acceptable salt thereof and the combination is synergistic. Another aspect of the invention relates to the treatment of cancer with indibulin as a single agent. Another aspect of the invention relates to dosing regimen for administration of oral dosage forms of indibulin.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=5&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20140004192": {
    "inventor": "Amedio, JR.; John C.; et al.",
    "report_date": "January 2, 2014",
    "title": "PHARMACEUTICAL FORMULATIONS OF INDIBULIN AND USES THEREOF",
    "abstract": "The present invention relates to pharmaceutical formulations that increase the solubility and bioavailability of indibulin, such as a spray-dried solid dispersion of indibulin with at least one matrix polymer. The invention further provides dosage formulations comprising the dispersion and processes for making the dispersion. The present invention also discloses a method of treating immune system based disorders, hyper-proliferative disorders, angiogenesis, malignancies, and neoplasms with the indibulin formulations disclosed herein.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20130261082": {
    "inventor": "WALLNER; Barbara; et al.",
    "report_date": "October 3, 2013",
    "title": "Combination Therapy With Organic Arsenicals",
    "abstract": "The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-I or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-I in combination with another therapeutic agent. Another aspect of the invention relates to a kit comprising SGLU-I and another therapeutic agent.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=7&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20130196000": {
    "inventor": "EINHORN; Lawrence; et al.",
    "report_date": "August 1, 2013",
    "title": "COMBINATION THERAPY INCLUDING ISOPHOSPHORAMIDE MUSTARD, ANALOGS, OR SALTS THEREOF",
    "abstract": "In one aspect, a method for treating a subject having a hyperproliferative disorder is disclosed, including administering to the subject a composition including: IPM, an IPM analog, or a pharmaceutically acceptable salt thereof in the dosage from about 70 mg/m.sup.2/day to about 160 mg/m.sup.2/day; etoposide in the dosage up to about 100 mg/m.sup.2/day; and one or more of carboplatin, cisplatin, oxaliplatin, picoplatin, or a combination thereof in the dosage of from AUC 2 mg/mL/min to AUC 7 mg/mL/min; wherein the treatment does not result in a dose limiting toxicity.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=8&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20130142730": {
    "inventor": "GUTSCH; Paul; et al.",
    "report_date": "June 6, 2013",
    "title": "COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER",
    "abstract": "The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=9&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20130084345": {
    "inventor": "Wallner; Barbara P.; et al.",
    "report_date": "April 4, 2013",
    "title": "INDIBULIN THERAPY",
    "abstract": "The invention provides combination therapy, wherein one or more other therapeutic agents are administered with indibulin or a pharmaceutically acceptable salt thereof and the combination is synergistic. Another aspect of the invention relates to the treatment of cancer with indibulin as a single agent. Another aspect of the invention relates to dosing regimen for administration of oral dosage forms of indibulin.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=10&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20120295861": {
    "inventor": "WALLNER; Barbara P.; et al.",
    "report_date": "November 22, 2012",
    "title": "Combination Therapy With Organic Arsenicals",
    "abstract": "The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-I or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-I in combination with another therapeutic agent. Another aspect of the invention relates to a kit comprising SGLU-I and another therapeutic agent.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=11&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20120219597": {
    "inventor": "Amedio, JR.; John C.",
    "report_date": "August 30, 2012",
    "title": "PHARMACEUTICAL FORMULATIONS FOR INDIBULIN",
    "abstract": "In certain embodiments, the invention relates to pharmaceutical formulations of an indolyl-3-glyoxylic acid derivative or a pharmaceutically acceptable salt thereof, such as indibulin. Methods of preparing such formulations and methods of treatment using these formulations are also described.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=12&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20120022229": {
    "inventor": "Gutsch; Paul; et al.",
    "report_date": "January 26, 2012",
    "title": "COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER",
    "abstract": "The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=13&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20110118209": {
    "inventor": "Gale; Robert Peter",
    "report_date": "May 19, 2011",
    "title": "SALTS OF ISOPHOSPHORAMIDE MUSTARD AND ANALOGS THEREOF AS ANTI-TUMOR AGENTS",
    "abstract": "The present disclosure relates to salts and compositions of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formula ##STR00001## wherein A.sup.+ represents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and formulating pharmaceutical compositions thereof. Methods for administering the disclosed compounds to subjects, particularly to treat hyperproliferative disorders, also are disclosed.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=14&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20100311689": {
    "inventor": "Wallner; Barbara P.; et al.",
    "report_date": "December 9, 2010",
    "title": "COMBINATION THERAPY WITH ORGANIC ARSENICALS",
    "abstract": "The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-1 or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-1 in combination with another therapeutic agent. Another aspect of the invention relates to a kit comprising SGLU-1 and another therapeutic agent.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=15&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20080255056": {
    "inventor": "Amedio; John C.; et al.",
    "report_date": "October 16, 2008",
    "title": "Salts of isophosphoramide mustard and analogs thereof",
    "abstract": "Disclosed herein are crystalline compounds of formula (I) ##STR00001## wherein A.sup.+ represents a hydroxylated aliphatic ammonium species; and X and Y independently represent leaving groups.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=16&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20080241274": {
    "inventor": "Wallner; Barbara P.; et al.",
    "report_date": "October 2, 2008",
    "title": "Indibulin therapy",
    "abstract": "The invention provides combination therapy, wherein one or more other therapeutic agents are administered with indibulin or a pharmaceutically acceptable salt thereof and the combination is synergistic. Another aspect of the invention relates to the treatment of cancer with indibulin as a single agent. Another aspect of the invention relates to dosing regimen for administration of oral dosage forms of indibulin.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=17&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20080139629": {
    "inventor": "Wallner; Barbara P.; et al.",
    "report_date": "June 12, 2008",
    "title": "Method for controlling angiogenesis in animals",
    "abstract": "Disclosed are methods for the inhibition of angiogenesis comprising administering an organic arsenical compound.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=18&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  },
  "20070183972": {
    "inventor": "Gutsch; Paul; et al.",
    "report_date": "August 9, 2007",
    "title": "Compounds and methods for the treatment of cancer",
    "abstract": "The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.",
    "link": "http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=19&f=G&l=50&co1=OR&d=PG01&s1=%22ZIOPHARM+Oncology%22.AS.&s2=%22ZIOPHARM+Oncology%22.AANM.&OS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22&RS=AN/%22ZIOPHARM+Oncology%22+OR+AANM/%22ZIOPHARM+Oncology%22"
  }
}